Randomized trial finds no significant reduction in late-stage cancer diagnoses among patients — Evidence Review
Published by researchers at NHS, Grail
Researched by
— the AI search engine for science
Table of Contents
A major randomized trial led by the NHS and Grail found that the Galleri multi-cancer blood test did not deliver a statistically significant reduction in late-stage cancer diagnoses. This result contrasts with earlier observational studies suggesting promise, and highlights ongoing debate in the field about the clinical utility of such tests.
- While earlier clinical validation studies showed high specificity and the feasibility of blood-based multi-cancer early detection (MCED) tests, these were not randomized controlled trials and did not assess outcomes like late-stage diagnosis reduction or mortality benefit 1 2 5.
- Related studies indicate that MCED tests can detect cancer signals with reasonable accuracy and may assist diagnosis, particularly in symptomatic populations, but evidence for improved patient outcomes in asymptomatic, screened populations remains limited 2 5 8.
- The reliance on "stage shift" (detecting cancers at earlier stages) as a surrogate for mortality reduction is debated in the literature, with some studies supporting its association with lower mortality 9, while others caution that this is not always a reliable endpoint across different cancer types 8.
Study Overview and Key Findings
The promise of a blood test capable of detecting over 50 types of cancer at early, more treatable stages has generated significant interest. The NHS-Galleri trial was the first large-scale randomized controlled trial of a multi-cancer early detection (MCED) test in an asymptomatic population. Its primary goal was to establish whether adding the Galleri test to standard NHS cancer screening would reduce the proportion of late-stage (stage III and IV) cancer diagnoses—a critical measure, as late-stage cancers are generally less treatable and have poorer outcomes. Despite high hopes and encouraging results from prior observational studies, the trial did not meet its primary endpoint, prompting careful reevaluation of the test's clinical value and role in population screening.
| Property | Value |
|---|---|
| Organization | NHS, Grail |
| Population | Patients aged 50 to 77 with no cancer symptoms |
| Sample Size | n=142,942 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Reduction in late-stage cancer diagnoses |
| Results | Trial failed to reduce late-stage cancer diagnoses statistically |
Literature Review: Related Studies
To place the new findings in context, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant studies:
Key Topics and Findings
| Topic | Key Findings |
|---|---|
| How accurate and feasible are multi-cancer early detection (MCED) blood tests? | - MCED blood tests show high specificity and moderate sensitivity, especially for advanced cancers, and can detect signals across many cancer types 1 2 3 5. - Feasibility is supported in both clinical validation and real-world diagnostic settings, including in symptomatic and screening populations 2 5. |
| Does detecting cancers at earlier stages ("stage shift") lead to improved outcomes? | - Observational and modeling studies suggest stage shift may lead to lower mortality, but the association varies by cancer type and is not always a reliable surrogate for mortality benefit 8 9 10. - Randomized screening trials for specific cancers have shown that large reductions in late-stage diagnoses often correspond to mortality reductions 9. |
| What is the impact of multi-cancer screening on population health and screening programs? | - Large-scale screening programs for specific cancers (e.g., bowel, lung) in the NHS have improved early detection and outcomes, but integrating MCED tests may face challenges such as false positives and variable performance across cancer types 11 12 13 14. - Socioeconomic factors and program implementation details can affect uptake and impact 12. |
How accurate and feasible are multi-cancer early detection (MCED) blood tests?
Recent non-randomized studies have established the technical feasibility and diagnostic accuracy of MCED blood tests, especially for detecting advanced-stage cancers. These tests tend to have high specificity (low false positive rates), but sensitivity for detecting early-stage disease is modest. Feasibility for clinical implementation has been demonstrated in various settings, including among asymptomatic individuals and those referred for diagnostic workup.
- MCED tests using cell-free DNA methylation profiling achieved high specificity (over 99%) in detecting cancer signals, and can accurately predict the cancer's tissue of origin 1 5.
- Sensitivity is higher in advanced-stage cancers compared to early-stage disease (e.g., 16–24% for stage I, rising to >90% for stage IV) 1 5.
- Feasibility studies in both screening and symptomatic populations confirm that MCED testing can be integrated into clinical pathways, but positive predictive value is higher in symptomatic groups 2 5.
- Pilot studies using alternative biomarker strategies (e.g., extracellular vesicle proteins) also show potential but require further validation 3.
Does detecting cancers at earlier stages ("stage shift") lead to improved outcomes?
"Stage shift"—the goal of moving diagnoses to earlier, more treatable stages—is a central concept in cancer screening trials. However, the relationship between stage shift and actual mortality reduction is complex and varies by cancer type.
- Meta-analyses of randomized cancer screening trials show a strong association between reductions in late-stage diagnoses and reductions in cancer-specific mortality, particularly when the reduction is substantial (>20%) 9.
- Mathematical modeling projects that MCED trials could achieve significant downstaging for cancers not covered by existing screening, but the magnitude of benefit depends on test sensitivity and cancer biology 10.
- Some analyses caution that stage shift is not always a reliable surrogate for mortality reduction, as survival gains differ between cancers and stages, and overdiagnosis or lead-time bias can complicate interpretation 8.
What is the impact of multi-cancer screening on population health and screening programs?
Population-based cancer screening programs have demonstrated benefits in detecting cancers earlier and improving outcomes. However, the integration of MCED tests into established screening pathways presents practical and ethical challenges, including variable test performance, impact on health inequalities, and ensuring appropriate follow-up for positive results.
- The NHS Bowel Cancer Screening Programme and UK lung cancer screening pilots have improved early detection rates, but highlight the importance of minimizing harms such as false positives and unnecessary procedures 11 13 14.
- Socioeconomic disparities can impact screening uptake, and interventions such as enhanced reminder letters can help reduce inequalities 12.
- MCED tests may complement rather than replace existing single-cancer screening, especially given current limitations in sensitivity for early-stage disease and variable performance across cancer types 1 5.
Future Research Questions
Despite significant progress, the field faces important unanswered questions. More research is needed to clarify the clinical utility, cost-effectiveness, and long-term impacts of MCED tests in real-world populations.
| Research Question | Relevance |
|---|---|
| What is the impact of multi-cancer blood testing on cancer mortality in asymptomatic populations? | This question addresses whether earlier detection via MCED actually translates into lower cancer-specific and all-cause mortality, which remains unproven in large RCTs 8 9. |
| How does test sensitivity for early-stage cancers vary across different MCED platforms? | Understanding variation in early-stage detection is crucial, as most current tests have higher sensitivity for late-stage cancers, limiting their preventive value 1 3 5. |
| What are the psychosocial and health system impacts of false positive MCED test results? | False positives can lead to unnecessary anxiety, invasive testing, and healthcare costs; quantifying these impacts is necessary for responsible implementation 2 5 14. |
| Can MCED tests be effectively targeted to high-risk populations? | Targeted use in populations with higher baseline risk (e.g., those with family history or other risk factors) may improve positive predictive value and cost-effectiveness 5 13. |
| How should MCED tests be integrated with existing cancer screening programs? | Integration strategies will affect uptake, patient pathways, and health system resource allocation; research is needed to optimize synergy and minimize harm 1 11 12. |
Overall, while the NHS-Galleri trial represents a landmark in large-scale MCED research, its neutral results on late-stage diagnosis reduction underscore the need for more evidence on clinical utility, mortality benefit, and efficient integration into health systems. Ongoing and future studies will be critical in determining the ultimate role of MCED blood tests in cancer prevention and control.